{
  "id": 14969989,
  "title": "Piper Sandler raises Opko Health stock price target on LabCorp deal",
  "url": "https://urgent.news/2026/10/16/piper-sandler-raises-opko-health-stock-price-target-on-labcorp-deal",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T14:10:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-raises-opko-health-stock-price-target-on-labcorp-deal-93CH-4954393"
  },
  "original_language": "en",
  "account": "Piper Sandler has increased its price target for Opko Health stock (NASDAQ: OPK) to $4.00, up from $3.00, while keeping an Overweight rating. The company's stock is trading at $1.66, up over 17% in the past week, and near its 52-week high of $1.75.\n\nOpko Health recently sold its remaining BioReference laboratory testing business, including the 4Kscore test, to LabCorp for $722 million upon close, with an additional $150 million potential based on 4Kscore revenues. As of the second quarter of 2026, Opko Health had $314.4 million in cash and $349 million in debt. The company holds a strong current ratio of 3.35, indicating liquid assets exceed short-term obligations.\n\nOpko Health's ModeX is conducting Phase I studies of various drugs, with data expected in late 2026 or early 2027. The company is also starting a Phase I study of subcutaneous oxyntomodulin analog OPK-88006, with data anticipated in the second half of 2027.\n\nOpko Health reported solid Q2 2026 results, with total revenue of $163.6 million, a 4.3% increase year-over-year. Pharmaceuticals revenue grew by 5.4% to $42.9 million, while Rayaldee revenue reached $8.1 million, up from $7.2 million in Q2 2025. The company's loss per share was smaller than expected at $0.01, compared to the forecasted $0.08 loss, driven by improved performance in diagnostics and pharmaceutical businesses.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Piper Sandler lowers Home Bancshares price target to $34 on growth",
        "url": "https://urgent.news/2026/10/16/piper-sandler-lowers-home-bancshares-price-target-to-34-on-growth",
        "published": "2026-10-16T14:10:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}